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Abstract
Background: Macrophages play an integral role in the host immune system, bridging innate and adaptive
immunity. As such, they are finely attuned to extracellular and intracellular stimuli and respond by rapidly
initiating multiple signalling cascades with diverse effector functions. The macrophage cell is therefore an
experimentally and clinically amenable biological system for the mapping of biological pathways. The goal
of the macrophage expression atlas is to systematically investigate the pathway biology and interaction
network of macrophages challenged with a variety of insults, in particular via infection and activation with
key inflammatory mediators. As an important first step towards this we present a single searchable
database resource containing high-throughput macrophage gene expression studies.
Description:  The GPX Macrophage Expression Atlas (GPX-MEA) is an online resource for gene
expression based studies of a range of macrophage cell types following treatment with pathogens and
immune modulators. GPX-MEA follows the MIAME standard and includes an objective quality score with
each experiment. It places special emphasis on rigorously capturing the experimental design and enables
the searching of expression data from different microarray experiments. Studies may be queried on the
basis of experimental parameters, sample information and quality assessment score. The ability to compare
the expression values of individual genes across multiple experiments is provided. In addition, the database
offers access to experimental annotation and analysis files and includes experiments and raw data
previously unavailable to the research community.
Conclusion: GPX-MEA is the first example of a quality scored gene expression database focussed on a
macrophage cellular system that allows efficient identification of transcriptional patterns. The resource will
provide novel insights into the phenotypic response of macrophages to a variety of benign, inflammatory,
and pathogen insults. GPX-MEA is available through the GPX website at http://www.gti.ed.ac.uk/GPX.
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Background
Macrophages are one of the most intensively studied cells
of the immune system. They have been shown to play a
key role in both the innate and adaptive immune
response and are capable of responding to a range of sig-
nals leading to classical or alternative activation of
immune responses which may be classified as innate, cel-
lular, or humoral, [1]. Their function as a mobile unicel-
lular system make them an ideal biological model for
taking a systems perspective to pathway analysis, and in
silico models of the macrophage cell and signalling path-
way are beginning to emerge [2]. Clinically, macrophages
are increasingly recognised as key determinants of a wide
range of diseases including cancer, atherosclerosis, infec-
tion, inflammation and auto-immunity. Because of the
broad spectrum of biological processes and pathological
conditions involving macrophages, studies and data on
macrophage biology are highly heterogeneous and dis-
persed. There is an emerging need to integrate diverse
studies and provide highly reliable datasets for systems
level analysis in this cell system. At the Scottish Centre for
Genomic Technology and Informatics (GTI), we have
developed the GPX-Macrophage Expression Atlas (GPX-
MEA). The GTI is a founder member of the Integrated
Macrophage Biology Group (IMBG), which is a network
of institutes with interests in a wide variety of macrophage
related research topics, such as inflammation, infectious
disease, cancer biology and immunity. Notably, all mem-
bers of the IMBG have a common interest in elucidating
key pathways within the macrophage and the network
allows researchers to contribute a variety of biological
knowledge and experimental and computational tech-
niques to this area.
GPX-MEA is a gene expression database that stores
MIAME-compliant [3] microarray experiments and associ-
ated data from a variety of human and murine macro-
phage cell types following treatment with pathogens and
immune modulators. This was accomplished by the colla-
tion of macrophage microarray studies from a diverse
group of private and public resources followed by valida-
tion and curation into a central database. GPX-MEA com-
plements other larger gene expression repositories such as
GEO [4] and ArrayExpress [5] by providing focussed data-
sets and comparative facilities for macrophage biologists,
immunologists and those interested in systems biology.
This enables the researcher for the first time to rapidly
search gene expression values from a number of experi-
ments involving different macrophage types, under
diverse conditions within a single resource. Furthermore,
GPX-MEA provides a coherent group of annotated raw
analysis files that can be used by the computational biol-
ogist for systems level analysis.
A major challenge when using microarray data to eluci-
date molecular pathways is the development of methods
for the reliable comparison of results from different stud-
ies. This issue is further compounded by the fact that
microarray assays are highly sensitive to technical pertur-
bations and the lack of standard units of gene expression.
It has been shown that microarray experiments, even
using the same platform, can vary greatly between groups
and laboratories [6]. In an attempt to address this issue in
GPX-MEA, a quality assessment score for each experiment
in the database is derived using defined criteria to give
users an indication of the underlying quality of the exper-
iment design, quality control and data structures. This
score can also be used to retrieve experiments based on
their quality requirements using the GPX-MEA web inter-
face.
Here we report on the data curation process, quality
assessment, content, search facilities and integration tools
that are components of the GPX-MEA.
Construction and content
Construction
GPX-MEA is part of the GPX database system at the Scot-
tish Centre for Genomic Technology and Informatics
(GTI, http://www.gti.ed.ac.uk). The GPX system com-
prises two MIAME-compliant microarray databases, GPX
Repository and GPX Discovery. The data is first curated
into GPX Repository, a biochip Laboratory Information
Management System developed at the GTI. GPX Reposi-
tory is designed around a set of web enabled data entry
forms that assist in the data capture process ensuring that
MIAME-compliant information is obtained.
On completion of curation, experiments are migrated
from GPX Repository to GPX Discovery. GPX Discovery
has been designed with web interfaces which allow the
user to query and retrieve data within GPX-MEA. It also
has the additional functionality of being able to retrieve
and compare individual probe signal intensity values
across experiments.
The underlying database schema of GPX Discovery, maxd-
SQL-Plus, is an enhanced version of maxdSQL 1.2 (maxd,
http://bioinf.man.ac.uk/microarray/maxd/). Enhance-
ment to the maxdSQL schema include extensions to store
image analysis files and annotations from the NCBI Uni-
Gene database [7].
Data within the GPX-MEA is accessed through a web-
based user interface developed at the GTI and imple-
mented using Perl and an Apache-mod_perl server. The
web application interfaces with an Oracle 9iR2 relational
database management system to search and retrieve the
experimental data. The schema, scripts, tools and docu-BMC Genomics 2005, 6:178 http://www.biomedcentral.com/1471-2164/6/178
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mentation are available at http://www.gti.ed.ac.uk/GPX/
software.
Data acquisition
GPX-MEA contains gene expression data from microarray
experiments conducted on a variety of human and murine
macrophage cell types challenged with pro-inflammatory,
anti-inflammatory, benign and pathogen insults.
Microarray studies fulfilling these biological criteria were
collated from a survey of five major gene expression
repositories (GEO [4], ArrayExpress [5], SMD[8], RAD [9]
and CIBEX [10]). In addition to experiments submitted to
public microarray repositories, GPX-MEA includes experi-
ments and associated data selected from a survey of over
2500 publications in the field of macrophage immunol-
ogy and infection. This combined approach to data colla-
tion was adopted in an attempt to consolidate data which
had previously been scattered among a variety of reposi-
tories and laboratories.
The investigators of each experiment selected for inclu-
sion in the database were contacted and asked to supply
raw image and image analysis files (Affymetrix DAT and
CEL files), and any MIAME information that were not
reported in the original publication or database entry.
Responses were received from eleven of the initial eight-
een investigators contacted to supply data and informa-
tion to GPX-MEA.
In addition to experimental information and data
obtained from the public domain, GPX-MEA also con-
tains original unpublished microarray experiments con-
ducted at the GTI. These experiments characterise the gene
expression profile of murine bone marrow derived macro-
phages grown under standard and serum free growth con-
ditions. Information and associated data files for these
and other experiments may be retrieved from GPX-MEA
using the GPX Discovery web interface.
Data curation
Data submitted to the GPX-MEA has followed a manual
curation process. At present, subjective evaluation criteria
are employed during the quality assessment of microarray
data. As a result, expert manual curation was undertaken
to ensure the value and biological relevance of informa-
tion held within the GPX-MEA. Efforts in the future will
be directed to methods for the automation of this process.
The curation process follows standard operating proce-
dures that include the assessment of the experiment data
against defined criteria and validation of experiment
information against MIAME standards.
For this first public release of GPX-MEA, studies con-
ducted using the Affymetrix GeneChip® platform have
been preferentially selected since they have widely recog-
nised quality control parameters, use of standardized
manufacturing and experimental protocols and familiar-
ity of the platform with the biological and computational
users. Future releases of GPX-MEA will contain experi-
ments hybridized using spotted custom array platforms
and other proprietary platforms, such as those from Agi-
lent and GE Healthcare.
Before submission to the database, analysis files were all
processed using the same software program and normali-
sation algorithm. Affymetrix DAT files were processed
using Affymetrix-Gene Chip Operating System (GCOS).
The CHP files were generated from CEL files using Affyme-
trix Global scaling normalisation to a Target Intensity
Value of 100 (TGT-100). In some instances DAT files were
unavailable and the original CEL files were used to gener-
ate the CHP files. The use of this global normalization
algorithm provides a uniform measure which allows a
preliminary comparison of expression values across
experiments within the databases. Other values that are
stored within the database from the CHP files are the
detection call (P, M, A) and the p-value of detection.
Quality assessment
GPX-MEA contains experiments of varying complexity
and experimental design collated from a variety of
resources. To take into account the variations in quality
and statistical power of experiments a GTI-derived ordinal
scale quality assessment score is assigned to each experi-
ment added to the database. The score enables the user to
make an informed judgement on the reliability of results
obtained from experiments within GPX-MEA and allows
for experiment selection based on quality requirements. It
also functions to provide a metric for systems biologist
interested in integrating data sets from the database.
The quality assessment score ranges from 0 (low) to 28
(high) and is derived from six defined categories each
with a 3-point (0, 1, 2) scale. The score is also stored as a
percentage of the maximum attainable value within the
database. Categories are also weighted by relative impor-
tance of the assessment on a 3-point (1, 2, 3) scale. The
scoring categories are as follows: use of consistent stand-
ard operating procedures (SOPs) [11], sample quality
control, the number of biological replicates in the study,
and finally, variation levels and data distributions [12-
14]. All scoring categories, scoring levels and weightings
are pre-determined (Table 1) and can be viewed using the
GPX Discovery interface. Categories and assessment tools
were selected after extensive discussion between biologi-
cal investigators, statisticians and bioinformaticians. This
process was informed by the GTI's experience in highBMC Genomics 2005, 6:178 http://www.biomedcentral.com/1471-2164/6/178
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Table 1: Quality Assessment Criteria for GPX-MEA
Assessment category Tool Weight (Score)Criteria
Standard Operating Procedures 
(SOPs)
Experiment description/protocol 2 2 – Standard Operating Procedures have been documented 
and followed.
1 – Only partial SOPs have been documented applied or 
followed
0 – SOPs not known or not followed
Sample size Experiment description/protocol 3 2 – Number of independent biological samples exceeds 5 per 
group, allowing for reasonably high statistical power in the 
hypothesis testing.
1- 3–5 independent biological samples per group, allowing to 
apply minimum level of statistics
0 – 1 or 2 independent biological samples per group (e.g. 
pilot experiment), reducing the applicability of statistics.
Image quality Image scan or numerical 
representation (Affymetrix)
3 2 – No signs of chip defects, background noise (RawQ) 
within 5 point range of each other. Scaling factor within 1–2 
fold range.
1 – Isolated chip defects, RawQ within 5 point range, scaling 
factor 1–3
0 – Systematic chip defects, saturation, RawQ outside 5 
point range, scaling factor greater than 3.
Target sample quality Electropherogram, UV-
Spectrophotometer
1 2 – Presence of 18S and 28S ribosomal subunits with no sign 
of degradation in any sample (RNA integrity). Absorbance 
ratio of A260/280 close to 2 (RNA purity) [16]. 1 – Either 
RNA integrity or purity criteria are met. 0 – Neither 
integrity nor purity criteria are met, or sample quality 
assessment was not performed, or no information provided.
Sample level data variation/
distribution
Box-and-whisker plots, supporting 
MA plots if required.
3 2 – Very consistent array medians and Inter-Quartile-Ranges 
across all samples before normalisation procedures (note: 
underlying assumption is that any treatments/conditions 
should not cause differential expression in more than 5–10% 
of all gene probes on the array.) 1 – Very small number of 
inconsistent data distributions with assumptions of a 
correctable difference in array signal intensity met (all genes 
on array affected, inter-array gene relationships are linear or 
global differences are expected, e.g. LPS treatment). 0 – 
Inconsistent median signal levels and spread (IQR) of data 
throughout the experiment, no biological explanation given.
Gene level data variation Coefficient of Variation versus 
Mean Expression plots
2 2 – Coefficient of Variation for majority of genes across all 
replicates within a sample group is less than 20%. Genes 
above this CV level are mostly in the lower signal range (due 
to measurement error). 1 – A small proportion of all genes 
has higher CV values than 20%, with a small number of these 
in the medium to high expression range. 0 – A large 
proportion of genes has a CV above 20% across most of the 
expression range.
A quality control assessment is made for each experiment curated into GPX-MEA. The quality assessment score is calculated using quantitative and 
qualitative scores in different areas; use of Standard Operating Procedures, the number and use of independent biological replicates, quality of 
image, sample quality control and structure of numeric data (spread, reproducibility). A combination of the different areas is used to give a total 
quality assessment score. This score can be used to indicate the quality of the underlying experiment in the database and as such is subject to 
interpretation. Where data is unavailable for assessment no score is assigned.
throughput microarray experimentation and took in con-
sideration published literature[11,12,14-18]. Initially an
additional assessment category was used that assigned a
score to the biological relevance of the experiment. This
criterion was omitted from the final assessment system so
that the score was focussed on technical sources of varia-
tion in the study. This resulted in a more reproducible
scoring methodology.
It is worth noting that given the complexity and variety of
experimental designs and data structures, it is not feasible
to develop fully objective criteria based on non-arbitrary
threshold values, instead we have sought to provide the
user with a graded indication of the underlying quality of
an experiment with a scoring system that is reproducible.
The first step in scoring an experiment is to obtain MIAME
compliant information about an experiment's design and
implementation. Using this information the score for
SOPs, sample size and sample quality control can be
assigned. The next criterion assesses image files and
includes analysis of the background noise (RAWQ) andBMC Genomics 2005, 6:178 http://www.biomedcentral.com/1471-2164/6/178
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variation in mean signal intensity (Scaling Factor) for the
arrays. The final criterion seeks to measure sample level
variation and gene level variation from visualizations out-
put using R and Bioconductor[19] software from the raw
image analysis files. Scores are assigned to each experi-
ment by the curator based on the criteria in Table 1.
To illustrate the assessment method the scoring of the cat-
egory "sample size" is described. In the category "sample
size", the number of biological replicates per group is
determined and scored using the criteria in table 1. In the
case of an experiment with 3 biological replicates per
group a mid score of 1 is assigned. After the initial score is
calculated, it is adjusted by relative importance using the
weighting of the category. The sample size category is
deemed of high importance[15,17,18] and is given a
weighting of 3, therefore the initial score of 1 is multiplied
by the category weighting 3, and assigned a value of 3.
A record detailing the score in each category for an indi-
vidual experiment can be viewed using GPX-MEA. Fur-
ther, the combined overall percentage score can be used to
select and retrieve experiments using the GPX Discovery
interface.
Future versions of GPX-MEA will incorporate non-
Affymetrix experiments. This will require modifications to
the scoring system which are likely to include; more strin-
gent requirements for the numbers of biological replicates
used in custom arrays based experiments, due to the larger
noise variation, the use of different visualisation tech-
niques to assess quality and an additional criterion to
address the suitability of the reference sample.
Data content
The current release of GPX-MEA (May 2005) consists of
11 public microarray experiments with a total of 152
hybridizations from 3 Affymetrix GeneChip® platforms
(Table 2). Eight of the eleven experiments have an associ-
ated literature publication [20-26]. These experiments
include the treatment of human or murine macrophages
with a range of agents including viral infection (e.g.
murine cytomegalovirus), treatment with cytokines (e.g.
IFN-alpha, IFN-beta, IFN-gamma, IL-4, IL-6) and serum
withdrawal. In addition, the effects of these treatments
had been examined using a range of macrophage geno-
types in the mouse (wild type, PIAS-/-, IRF1-/-, SOCS3-/-).
At present, GPX-MEA has a further 12 MIAME-compliant
experiments with a total of 246 hybridizations stored in a
restricted access site. This allows the accommodation of
unpublished microarray experiments. Experiments within
this access controlled site will be made publicly accessible
following scientific publication. Further macrophage gene
expression studies have been identified for deposition in
the GPX-MEA database and routine updates to the data-
base are scheduled to include emerging research findings.
Utility
Search pages
Users can browse and retrieve data from GPX-MEA using
the user oriented GPX Discovery web based graphical
interface http://www.gti.ed.ac.uk/GPX. Searches can be
performed in three different sections of the interface;
experiments, arrays and probes. A search is made using a
number of separate criteria such as accession number,
technology type, target organism, quality assessment
score or keywords. For example, all microarray experi-
ments conducted using humans as the source organism
can be retrieved by performing a search selecting Homo
sapiens from the organism search field. The results of a
query are displayed in a table with hyperlinks to the cor-
responding experiment, array or probe record.
Table 2: Summary of microarray experiment in GPX-MEA.
Accession Experimental Factors Host 
Species
Cell types Hybridisations 
Count
Array Type Reference
GPX-000032                                        time, compound, genotype Mouse BMDMs 17 MG_U74Av2 [20]
GPX-000034                                        time, infection, compound Mouse BMDMs 12 MG_U74Av2 [21]
GPX-000035                                       compound,  genotype Mouse BMDMs 12 MG_U74Av2 [21]
GPX-000036                                        infection, cell type Human Dendritic cells, monocyte derived 
macrophages
28 HG_U95Av2 [26]
GPX-000037                                       compound,  protocol Human PBMCs 12 HG_U95Av2 [24]
GPX-000038                                       compound,  protocol Human PBMCs 18 HG_U95Av2 N/A
GPX-000039                                       time,  compound Mouse RAW264.7 3 MOE430A [25]
GPX-000040                                        time, compound, genotype Mouse BMDMs 10 MG_U74Av2 [23]
GPX-000041                                       infection Mouse Monocyte  derived macrophages 30 MG_U74Av2 [22]
GPX-000043                                       protocol Mouse BMDMs 6 MG_U74Av2 N/A
GPX-000045                                       protocol Mouse BMDMs 4 MG_U74Av2 N/A
BMDMs indicate cells are bone marrow derived macrophages. PBMCs indicate cells are peripheral blood mononuclear cells. N/A indicates 
experiments unpublished.BMC Genomics 2005, 6:178 http://www.biomedcentral.com/1471-2164/6/178
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Experiment
Experiments are defined in GPX-MEA as the complete set
of bioassays (hybridizations) and their descriptions for a
common purpose, following Microarray Gene Expression
Data Society (MGED) ontology specifications. Once an
experiment has been selected the corresponding database
entry is displayed. An experiment record shows the prov-
enance, experimental design, protocols, sample informa-
tion, array details, quality assessment and a list of array
measurements. Expression values can be selected from the
experiment record by selecting the desired measurement
records. Measurement data are presented to the users as a
comma separated value (CSV) file. Significantly, the user
can also obtain original image analysis files, e.g. the
Affymetrix CEL files, from the database providing addi-
tional flexibility for an extended analysis. Access to the
original image analysis files is an especially valuable
resource for those interested in computational analysis
and data integration.
Array type
The array type section allows the user to browse the list of
array types stored within the database. An array type
record displays the description of the array type and the
manufacturer. The array layout with probe annotation
obtained from a local copy of the UniGene database can
also be downloaded as a CSV file from a link within a
record.
Probe
The probe section allows the user to search and retrieve
individual probe details from the database based on crite-
ria such as Entrez Gene ID, Gene Symbol and UniGene
ID. Once a probe record is selected the user can view
probe annotation within the record and by following
links to external databases, Adapt[27], NetAffx [28] and
NCBI Gene[29]. The probe record also displays a list of
experiments associated with the probe. Using the list of
associated experiments, the user can compare the gene
expression levels for that probe across the GPX-MEA. For
example (Fig 1), the user searches for probes that target
the gene interferon regulatory factor 7 using the gene sym-
bol 'IRF7'. From the returned results the user selects a
probe record to view more details. From this probe record,
the user then selects the experiments within the database
to compare the gene expression levels. The results are for-
matted as a table containing signal intensities, Affymetrix
detection calls (P,M,A) and p-value of detections for every
measurement from the selected experiments. The signal
intensity of Affymetrix probe sets are the TGT-100 nor-
malised signal. The use of this consistent global normali-
sation algorithm within the database allows for a
preliminary comparison of probe expression levels
between the distinct microarray experiments.
Biolink MatchMaker
The Probe section provides a link to the BioLink Match-
Maker integration tool which enables the comparison of
different array types. BioLink MatchMaker uses NCBI's
UniGene Cluster IDs to identify probes which represent
equivalent genes on two different microarray platforms of
the same species stored within GPX-MEA. Users can also
submit a list of up to 1000 GenBank or UniGene ID to
identify probe matches with any array type in the database
using the Batch query function. Results can be displayed
either as HTML tables containing hyperlinks to the corre-
Comparison of the expression profile of IRF7 across three  experiments within GPX-MEA Figure 1
Comparison of the expression profile of IRF7 across 
three experiments within GPX-MEA. (A) From the 
probe search interface the user searches for the gene 'IRF7'. 
(B) From the probe record the user selects the experiments 
they wish to view expression values from. (C) A list of 
expression values for the probe is displayed alongside the 
measurement and experiment name.BMC Genomics 2005, 6:178 http://www.biomedcentral.com/1471-2164/6/178
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sponding UniGene entry or can be downloaded as a CSV
file for further analysis. For example, the Affymetrix Gene-
Chips® MG U74Av2 and MOE430A version 2 can be com-
pared using BioLink MatchMaker to find probes that share
equivalent genes. The results show that there are 7454
unique probe matches between the two platforms. The
user can then view the results in a separate webpage or
download the results for further analysis.
Future work
GPX-MEA is under active development and will continue
to collate macrophage expression studies through online
database searches and collaboration with principle inves-
tigators. This data will be assessed and manually curated
within the GPX-MEA and released in routine database
updates. In addition, experiments that profile the macro-
phage response to infection and immune regulators con-
ducted within GTI will also be included in the database.
There will also be continual development of curation and
quality assessment protocols to maintain the high stand-
ard of experimental description and data within the data-
base.
New analytical tools in development for the GPX-MEA
include the ability to query gene expression using interac-
tive immunological pathway maps and an automated sta-
tistical analysis tool to guide the user through
normalisation and analysis processes. The export of
MAGE-ML (Microarray Gene Expression-Markup lan-
guage) from the database is also being developed so that
data may be shared between other public repositories and
users of microarray data. In addition, GPX is part of the
Edinburgh National Translational Cancer Research Net-
work Centre resources (NTRAC) and relevant work emerg-
ing from this project will be included in GPX-MEA.
Conclusion
Here we present GPX-MEA, a MIAME compliant online
database that exploits and captures the wealth of expres-
sion studies related to macrophage biology data in a cen-
tralised resource. Experiments are assessed and submitted
to the database by expert curators and includes some
information and data, such as image analysis files, that
were not previously publicly available.
This is the first example of a focussed macrophage gene
expression database that allows efficient identification of
gene expression patterns in this key player in the host
immune system.
GPX-MEA also provides highly reliable datasets with asso-
ciated contextual information that can be used by the
computational biologist for systems level analysis. In
addition, it also utilises a unique quality assessment scor-
ing system that enables the user to select experiments
based on their quality requirements.
Availability
GPX-MEA is publicly available and can be accessed at
http://www.gti.ed.ac.uk/GPX using web browsers. The
GPX Discovery software is available for download at
http://www.gti.ed.ac.uk/GPX/software.
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